Azitra, Inc.

Snapshot

Azitra is a pre-clinical/early-clinical dermatology biotech with essentially no revenue and an $11.0M net loss in FY 2025. It holds $6.7M in cash, and Signal8 models roughly 3.1 months of runway against ongoing burn.

What's Happening Right Now

• Mon 26th Oct '26 · Cosmetic data: On October 26, 2026, Azitra reported ex vivo skin study results for its ATR-COSF cosmetic candidate showing reduced fine lines and better elasticity, with a first-in-human study planned and initial data expected by year end.
• Mon 26th Oct '26 · ATM sale: Sold $126 of stock / 100 shares through its at-the-market program, as stated for Sep 28, 2026 to Oct 26, 2026.
• Thu 22nd Oct '26 · Reverse split: Azitra completed a 1-for-10 reverse stock split effective October 26, 2026, aimed at curing a low share-price listing issue on NYSE American.
• Thu 1st Oct '26 · Trial progress: Azitra's Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated skin rash cleared its safety review and advanced to Cohort 2, enrolling about 24 more patients.
• Mon 28th Sep '26 · ATM offering: Azitra set up a $3.5 million at-the-market stock sale agreement on September 28, 2026, a filing that also disclosed the company paused its ATR-12 trial to preserve cash and that funds may not cover the next 12 months.
• Mon 28th Sep '26 · Offering: Priced a block sale under its at-the-market program for $126 in gross proceeds (closing not yet reported in the filings reviewed).
• Fri 21st Aug '26 · Listing compliance: On August 21, 2026, Azitra regained compliance with NYSE American's continued listing standards, removing the exchange's noncompliance flag.
• Tue 16th Jun '26 · Warrants: Issued warrants over 4.24M shares.